Crestor vs Amlodipine: Cost and Access Head-to-Head

These Two Drugs Serve Different Purposes

Rosuvastatin and amlodipine are not competitors. They target separate cardiometabolic risk factors and belong to different pharmacological classes. Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure.

The confusion between them often stems from the fact that both drugs appear in cardiometabolic treatment plans. A patient with metabolic syndrome may receive prescriptions for both on the same visit. The 2018 AHA/ACC cholesterol guideline recommends statins for patients with elevated ASCVD risk, while the 2017 AHA/ACC hypertension guideline positions amlodipine as a first-line antihypertensive. Neither guideline suggests choosing one drug over the other because they address distinct pathophysiology.

Prescribers sometimes need to prioritize one medication when patients resist polypharmacy. In those cases, the choice depends entirely on which risk factor poses the greater immediate threat. A patient with LDL of 190 mg/dL and normal blood pressure needs rosuvastatin first. A patient with stage 2 hypertension and borderline lipids needs amlodipine first. The decision is clinical, not economic, in most scenarios.

Generic Pricing Makes Both Drugs Affordable

At generic pricing, the cost difference between rosuvastatin and amlodipine is negligible. Both drugs cost between $4 and $15 per month at most retail pharmacies when purchased as generics. Walmart, Costco, and Mark Cuban's Cost Plus Drugs list both medications at the $4 to $6 range for a 30-day supply.

Brand-name Crestor tells a different story. AstraZeneca's branded rosuvastatin carries a wholesale acquisition cost (WAC) exceeding $350 per month. Generic rosuvastatin entered the U.S. market in 2016 after Crestor's patent expired, and prices dropped rapidly. By contrast, amlodipine lost patent protection in 2007 (the brand name Norvasc was manufactured by Pfizer), giving it nearly a decade longer of generic price erosion FDA Orange Book.

For uninsured patients paying cash, GoodRx data from early 2026 shows generic rosuvastatin 10 mg at $3.50 to $11.00 for 30 tablets and generic amlodipine 5 mg at $3.00 to $9.00 for 30 tablets. The practical takeaway: neither drug should create a significant financial barrier for most patients. When cost does become a factor, it is almost always because a prescriber wrote for brand-name Crestor specifically, or because the patient's insurer placed rosuvastatin on a higher formulary tier than expected.

According to a 2022 analysis published in JAMA Network Open, out-of-pocket costs for generic statins decreased by 76% between 2014 and 2021, making adherence less dependent on insurance status than it was a decade ago.

Insurance Coverage and Formulary Placement

Both generic rosuvastatin and generic amlodipine sit on Tier 1 (preferred generic) for the majority of commercial, Medicare Part D, and Medicaid formularies. Copays at Tier 1 range from $0 to $10 per month across most plans.

Differences emerge in two situations. First, some Medicare Part D plans still distinguish between atorvastatin (the most prescribed statin) and rosuvastatin on formulary placement. A small number of plans place rosuvastatin on Tier 2, which can mean a $15 to $25 copay instead of $0 to $10 CMS Medicare Plan Finder. Second, prior authorization requirements occasionally apply to rosuvastatin at higher doses (40 mg), though this is uncommon for the 5 mg, 10 mg, and 20 mg strengths.

Amlodipine faces almost no formulary restrictions. Its long generic history, broad indication set, and extensive safety record mean that payers rarely impose step therapy or prior authorization. The American College of Cardiology's 2017 pathway for hypertension names amlodipine among preferred first-line agents, which reinforces its unrestricted formulary status.

For patients on high-deductible health plans (HDHPs), both generics fall well below the threshold where the deductible becomes relevant. A 90-day supply of either drug through mail-order pharmacy typically costs $8 to $20, which most patients pay out of pocket before hitting their deductible regardless.

The JUPITER Trial: Rosuvastatin's Landmark Evidence

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy men and women with LDL cholesterol below 130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher. Participants received rosuvastatin 20 mg daily or placebo 1.

The trial was stopped early at a median follow-up of 1.9 years. Rosuvastatin reduced the primary endpoint (a composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% compared to placebo (hazard ratio 0.56; 95% CI 0.46 to 0.69; P<0.00001). LDL cholesterol dropped by 50%, and hsCRP fell by 37%.

Dr. Paul Ridker, the trial's principal investigator, stated: "JUPITER demonstrates that statin therapy can prevent first cardiovascular events even among individuals not currently recommended for treatment under existing guidelines." This finding expanded the eligible population for statin therapy and influenced the 2013 ACC/AHA cholesterol guideline revision.

Critics noted the early termination may have inflated the benefit estimate. A Cochrane review of statins for primary prevention confirmed a net benefit but with more modest absolute risk reductions than the relative numbers in JUPITER suggested. The number needed to treat (NNT) over 4 years to prevent one major CV event was approximately 95 in the Cochrane analysis of all primary-prevention statin trials.

ASCOT-BPLA: Amlodipine's Cardiovascular Case

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA) randomized 19,257 patients with hypertension and at least three additional cardiovascular risk factors to either an amlodipine-based regimen (adding perindopril as needed) or an atenolol-based regimen (adding bendroflumethiazide as needed) 2.

The trial was stopped early after a median of 5.5 years. The amlodipine-based regimen reduced all-cause mortality by 11% (P=0.025), stroke by 23% (P=0.0003), and total cardiovascular events and procedures by 16% (P<0.0001) compared to the atenolol-based arm. These differences persisted even after adjusting for the small blood pressure differences between groups (mean difference of 2.7/1.9 mmHg favoring amlodipine).

Professor Peter Sever, the lead investigator, noted: "The results suggest that the benefits of the amlodipine-based regimen extend beyond blood pressure reduction alone." Subsequent analyses pointed to amlodipine's more favorable metabolic profile, including less new-onset diabetes, as a contributing factor.

ASCOT also included a lipid-lowering arm (ASCOT-LLA) that tested atorvastatin 10 mg in a subset of patients. The combination of amlodipine plus atorvastatin showed particularly strong outcomes, providing indirect support for the strategy of combining a calcium channel blocker with a statin in high-risk patients 3.

Side Effect Profiles Affect Long-Term Adherence and Cost

Medication adherence directly affects total healthcare costs. A drug that is cheap but poorly tolerated generates costs through emergency visits, dose adjustments, and therapeutic switching.

Rosuvastatin's most common side effects include myalgia (reported in 3% to 5% of patients in clinical trials), headache, and gastrointestinal discomfort. Rare but serious effects include rhabdomyolysis and hepatotoxicity. The FDA label for rosuvastatin notes a dose-dependent increase in myopathy risk, particularly at the 40 mg dose. Asian patients metabolize rosuvastatin differently and the recommended starting dose is 5 mg in this population.

Amlodipine's most common side effect is peripheral edema, occurring in approximately 10% of patients at the 10 mg dose and 3% at the 5 mg dose. Headache, fatigue, and dizziness also occur. Unlike myalgia with statins, peripheral edema from amlodipine is a mechanical effect of arteriolar dilation and does not indicate organ damage. The 2023 ACC Expert Consensus on management of statin-associated muscle symptoms recommends a rechallenge strategy before concluding true statin intolerance, because the SAMSON trial (N=60) showed that 90% of statin side effects occurred equally on placebo 4.

Both drugs demonstrate high overall tolerability. Discontinuation rates in large observational studies remain below 10% for each at standard doses, suggesting that side effects rarely override the cost and access advantages both generics offer.

Who Should Take Both Drugs Together

The ASCOT-LLA sub-study demonstrated that patients on amlodipine who also received a statin had a 53% reduction in coronary events compared to amlodipine plus placebo. This combination is now standard practice for patients with both hypertension and dyslipidemia.

The 2019 ACC/AHA Primary Prevention Guideline identifies several groups who benefit from simultaneous lipid and blood pressure management: patients with type 2 diabetes over age 40, those with 10-year ASCVD risk exceeding 7.5%, and anyone with established atherosclerotic disease. For these patients, the question is not rosuvastatin or amlodipine. It is which dose of each.

Fixed-dose combination pills containing amlodipine plus a statin (such as Caduet, which combined amlodipine and atorvastatin) were previously marketed by Pfizer. Caduet was discontinued in the U.S. in 2015, though generic versions of the combination remain available in some international markets. No fixed-dose combination of amlodipine plus rosuvastatin is currently marketed in the U.S.

Patients taking both medications separately should know that there is no pharmacokinetic interaction between amlodipine and rosuvastatin. They can be taken at the same time of day. Rosuvastatin does not require evening dosing (unlike some older statins), which simplifies the regimen.

Access Across the U.S.: Pharmacy Availability and Programs

Both drugs are stocked by virtually every retail pharmacy in the United States. Neither requires specialty pharmacy dispensing. Both appear on the $4 generic lists at Walmart, Kroger, and other major chains.

Patient assistance programs exist for both branded versions, though they are rarely needed at generic pricing. AstraZeneca's Crestor savings card could reduce brand copays to $3 per month for commercially insured patients. Pfizer's program for Norvasc offered similar discounts when the brand was still actively marketed. For uninsured patients, the Partnership for Prescription Assistance and NeedyMeds databases list multiple programs covering generic statins and antihypertensives.

Mail-order pharmacies through Express Scripts, CVS Caremark, and OptumRx typically offer 90-day supplies at lower per-unit costs than retail. For patients taking both medications chronically, a 90-day mail-order approach reduces the number of pharmacy visits and may improve adherence. A study in the American Journal of Managed Care found that mail-order pharmacy users had 14% higher medication adherence rates over 12 months compared to retail pharmacy users for chronic cardiovascular medications.

State Medicaid programs cover both generics without prior authorization in all 50 states. The Medicaid Drug Utilization Review database confirms that rosuvastatin and amlodipine rank among the most dispensed medications in every state Medicaid program.

Switching Between Drug Classes Is Not Standard Practice

Switching from Crestor to amlodipine (or vice versa) only makes clinical sense if the original diagnosis was incorrect or the patient's risk profile has changed. These are not therapeutic substitutes.

A statin-intolerant patient does not switch to a calcium channel blocker for cholesterol management. Instead, alternatives include ezetimibe, bempedoic acid, or PCSK9 inhibitors like evolocumab or alirocumab ACC/AHA Cholesterol Guideline. Similarly, a patient who cannot tolerate amlodipine does not substitute rosuvastatin for blood pressure control. Alternatives include ACE inhibitors, ARBs, or thiazide diuretics per JNC 8 panel recommendations.

The only scenario where a prescriber might remove one of these drugs involves reassessment of cardiovascular risk. If a patient achieves target blood pressure through weight loss and dietary changes, the clinician may deprescribe amlodipine. If a patient's 10-year ASCVD risk drops below the treatment threshold (through lifestyle modification or aging out of a risk window), a statin may be discontinued after shared decision-making. Neither scenario represents a drug-to-drug switch.

The Bottom Line on Value

Generic rosuvastatin and generic amlodipine both cost under $15 per month, are covered on Tier 1 by nearly all U.S. insurers, and require no prior authorization at standard doses. The JUPITER trial showed rosuvastatin 20 mg reduces major cardiovascular events by 44% in primary prevention patients with elevated hsCRP [1]. ASCOT-BPLA showed an amlodipine-based blood pressure regimen reduces total cardiovascular events by 16% versus atenolol-based treatment [2]. For patients with both hypertension and dyslipidemia, prescribing both drugs together, at a combined cost of under $25 per month at generic pricing, represents one of the highest-value interventions in preventive cardiology.